Plasminogen Activator Inhibitor-1 Promoter Polymorphism is Not Associated With the Aggressiveness of Disease in Prostate Cancer

H. Li, E. T. Shinohara, Q. Cai, H. Chen, R. Courtney, C. Cao, Z. Wang, M. Teng, W. Zheng, B. Lu

Research output: Contribution to journalArticle

4 Citations (Scopus)


Aims: PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer. Materials and methods: In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues of 98 Caucasian patients with prostate cancer. Results: The distribution of the genotypes is in Hardy-Weinberg equilibrium. The genotype had no statistically significant relationship with other prognostic factors. Similar risks for recurrence were seen in individuals with the 4G/4G and 4G/5G genotypes compared to those with 5G/5G genotype (odds ratio [OR] 2.65, 95% CI: 0.41-16.94, P = 0.30; OR = 2.19, 95% CI: 0.38-12.49, P = 0.38). Conclusion: We concluded that PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.

Original languageEnglish
Pages (from-to)333-337
Number of pages5
JournalClinical Oncology
Issue number4
Early online date15 Mar 2006
Publication statusPublished - 1 May 2006
Externally publishedYes


Cite this